Capricor Therapeutics

Capricor Therapeutics, Inc. (Nasdaq:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction, advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications.
Beverly Hills, US
Size (employees)
29 (est)
Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US

Capricor Therapeutics Office Locations

Capricor Therapeutics has office in Beverly Hills
Beverly Hills, US

Capricor Therapeutics Metrics

Capricor Therapeutics Summary

Market capitalization

$67 m

Closing share price

Capricor Therapeutics's current market capitalization is $67 m.

Capricor Therapeutics Financials

Capricor Therapeutics's revenue is $4.8 m in FY, 2014 which is a 13.2% decrease from the previous period.
FY, 2014FY, 2015Y, 2016


$4.8 m$5.5 m$4 m

Revenue growth, %


Net Income

($6.2 m)($12.9 m)

Capricor Therapeutics Market Value History

Capricor Therapeutics Online Presence

Capricor Therapeutics Company Life

You may also be interested in